AbGn-168H is under clinical development by AltruBio and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AbGn-168H’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AbGn-168H overview
AbGn-168H (neihulizumab) is under development for the treatment of moderate to severe chronic plaque psoriasis, steroid-refractory acute graft versus host disease (GVHD), psoriatic arthritis (PsA) and renal transplantation. The drug candidate is administered as an intravenous infusion. It is a monoclonal antibody that acts by targeting CD162 antigen. It was also under development for plaque psoriasis as a subcutaneous or intravenous infusion, type 1 diabetes and ulcerative colitis.
AltruBio overview
AltruBio is a clinical-stage biopharmaceutical company. It develops therapeutics for inflammatory and autoimmune diseases and cancers. The company’s product pipeline includes ALTB-168 and ALTB-268. It pipeline treats psoriatic arthritis, ulcerative colitis, steroid-refractory acute graft versus host disease, acute graft versus host disease, ulcerative colitis and solid organ transplantation. AltruBios’ therapeutics areas comprise gastric and pancreatic cancer, GI tumors, immune-mediated inflammatory diseases, antigen-positive cancer and colorectal cancers among others. The company operates its offices in the US and Taiwan. AltruBio is headquartered in Redwood, California, the US.
For a complete picture of AbGn-168H’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
